Cost-effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price.

ABSTRACT:

Introduction

An estimated 6 million Americans have Alzheimer's disease (AD). Aducanumab was recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data.

Methods

We developed a Markov state transition model of AD to estimate the cost effectiveness of aducanumab compared to standard of care (SOC) over a 5-year time horizon for a cohort of persons aged 65 with mild AD. Outcomes included quality adjusted life years (QALYs), discounted costs, and incremental cost-effectiveness ratios (ICERs). We performed sensitivity analyses to address uncertainty.

Results

Over 5 years, the incremental cost of aducanumab compared to SOC was $179,890. Aducanumab resulted in 0.47 QALYs gained compared to SOC. The ICER for aducanumab compared to SOC

SUBMITTER: Sinha P 

PROVIDER: S-EPMC8900580 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature